FDA Class II Recall for ACME UNITED CORPORATION's Sting Relief Swabs Signals Critical Product Mix-up and Supply Chain Risk
ACME UNITED CORPORATION faces an FDA Class II recall for 2,338 boxes of Sting Relief Swabs (Lot #: 2251994) due to a critical product mix-up. This nationwide recall, initiated September 23, 2025, signals significant quality control failures impacting supply chain integrity and brand reputation. Procurement and regulatory teams must assess ACME UNITED's remediation plans to mitigate future supply disruptions and ensure product safety.
FDA Initiates Class II Recall for ACME UNITED CORPORATION's Sting Relief Swabs: Immediate Supply Chain Disruption
The U.S. Food and Drug Administration (FDA) has classified the ongoing recall of ACME UNITED CORPORATION's Sting Relief Swabs as Class II, indicating a situation where the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This recall, identified as D-0122-2026, was voluntarily initiated by ACME UNITED CORPORATION on September 23, 2025, from their Shelton, CT location, impacting 2,338 boxes of the 'Sting Relief Swabs, First Aid Only, 10 Swabs per box, part number 19-001' product. The specific lot affected is 2251994, with an expiration date of September 30, 2029, and UPC 738743190015. The core reason for this action is a 'Product Mix-up,' a critical quality control failure that led to incorrect product packaging or labeling. For procurement directors, this means an immediate disruption to the supply chain for this specific first aid product, requiring swift action to identify affected inventory, halt distribution, and manage potential returns from retailers across the USA. Regulatory affairs heads must ensure that all internal and external stakeholders are informed and that the firm's response aligns with FDA expectations for a Class II recall, minimizing potential liability and maintaining consumer trust in ACME UNITED's product portfolio.
Commercial Repercussions of ACME UNITED's Nationwide Product Mix-up: Brand Integrity and Procurement Risks
The 'USA Nationwide' distribution pattern of the recalled Sting Relief Swabs amplifies the commercial repercussions for ACME UNITED CORPORATION and its partners. A product mix-up, particularly for an over-the-counter drug product, points to fundamental deficiencies in manufacturing processes, specifically in areas such as line clearance, material segregation, and labeling verification. Such an error suggests a breakdown in Good Manufacturing Practices (GMP) that could extend beyond this single product line. For business development executives, this incident poses a significant threat to brand reputation and market share, potentially eroding consumer confidence in the 'First Aid Only' brand and ACME UNITED's overall product quality. Supply chain VPs must now contend with the logistical complexities of retrieving 2,338 boxes from a broad distribution network, a costly and resource-intensive undertaking. Furthermore, this event necessitates a re-evaluation of ACME UNITED as a supplier. Procurement teams should initiate enhanced due diligence, potentially requiring additional audits of ACME UNITED's manufacturing facilities and quality management systems to ascertain the root cause of the mix-up and the robustness of their corrective and preventive actions (CAPA). Failure to address these underlying issues comprehensively could lead to future recalls, further jeopardizing supply continuity and increasing compliance risks for downstream partners.
ACME UNITED CORPORATION's Regulatory Compliance Path: Mitigating Future Supply Chain Vulnerabilities
With the recall status listed as 'Ongoing,' ACME UNITED CORPORATION is under continuous FDA scrutiny to ensure all affected product is accounted for and that robust corrective actions are implemented. Regulatory affairs heads must guide ACME UNITED through a comprehensive root cause analysis to pinpoint exactly how the product mix-up occurred and develop a detailed CAPA plan. This plan must not only address the immediate issue but also prevent recurrence across all relevant product lines. The FDA will expect evidence of effective implementation and verification of these actions. For supply chain VPs, this means potential delays in future product releases from ACME UNITED as the company dedicates resources to remediation and faces increased regulatory oversight. Business development executives should anticipate questions from major retailers and distributors regarding ACME UNITED's quality assurance protocols and long-term commitment to compliance. This event underscores the critical importance of a proactive quality culture and robust supplier qualification programs. Procurement directors should consider diversifying their supplier base for essential first aid components and finished products to mitigate risks associated with single-source dependencies, especially when a supplier demonstrates lapses in fundamental quality controls. Monitoring ACME UNITED's progress in resolving this Class II recall will be crucial for assessing their long-term reliability as a commercial partner.